These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8978257)

  • 21. "Serious" and "severe" adverse drug reactions need defining.
    Frankenfeld C
    BMJ; 2004 Sep; 329(7465):573. PubMed ID: 15345644
    [No Abstract]   [Full Text] [Related]  

  • 22. [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].
    Minei-Rachmilewitz T
    Harefuah; 1999 Jul; 137(1-2):25-7, 87. PubMed ID: 10959270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mefloquine has more adverse effects than other drugs for malaria prophylaxis.
    Eaton L
    BMJ; 2009 Oct; 339():b4167. PubMed ID: 19825970
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationships between mefloquine blood levels, gender, and adverse reactions.
    Wiedermann G; Kollaritsch H; Kundi M; Wernsdorfer WH
    Am J Trop Med Hyg; 2002 May; 66(5):445-6; author reply 446-7. PubMed ID: 12201572
    [No Abstract]   [Full Text] [Related]  

  • 25. Childhood mefloquine-induced mania and psychosis: a case report.
    Thapa R; Biswas B
    J Child Neurol; 2009 Aug; 24(8):1008-9. PubMed ID: 19295181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Better approach needed to detect and treat military personnel with adverse effects from mefloquine.
    Quinn JC
    BMJ; 2016 Feb; 352():i838. PubMed ID: 26865279
    [No Abstract]   [Full Text] [Related]  

  • 27. Mefloquine-induced eosinophilic pneumonia.
    Katsenos S; Psathakis K; Nikolopoulou MI; Constantopoulos SH
    Pharmacotherapy; 2007 Dec; 27(12):1767-71. PubMed ID: 18041895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults.
    Rendi-Wagner P; Noedl H; Wernsdorfer WH; Wiedermann G; Mikolasek A; Kollaritsch H
    Acta Trop; 2002 Feb; 81(2):167-73. PubMed ID: 11801224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eye disorders reported with the use of mefloquine (Lariam(®)) chemoprophylaxis--A drug safety database analysis.
    Adamcova M; Schaerer MT; Bercaru I; Cockburn I; Rhein HG; Schlagenhauf P
    Travel Med Infect Dis; 2015; 13(5):400-8. PubMed ID: 26119539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
    Nevin RL; Leoutsakos JM
    Drugs R D; 2017 Mar; 17(1):199-210. PubMed ID: 28063022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships between mefloquine blood levels, gender, and adverse reactions.
    MacArthur JR; Parise ME; Steketee RW
    Am J Trop Med Hyg; 2002 May; 66(5):445; author reply 446-7. PubMed ID: 12201573
    [No Abstract]   [Full Text] [Related]  

  • 32. First-time diagnosis of severe depression: induced by mefloquine?
    Whitworth AB; Aichhorn W
    J Clin Psychopharmacol; 2005 Aug; 25(4):399-400. PubMed ID: 16012293
    [No Abstract]   [Full Text] [Related]  

  • 33. Maculopathy associated with mefloquine (Lariam) therapy for malaria prophylaxis.
    Walker RA; Colleaux KM
    Can J Ophthalmol; 2007 Feb; 42(1):125-6. PubMed ID: 17361254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long-term malaria prophylaxis with mefloquine: a study of adverse drug reactions].
    El Jaoudi R; Benziane H; Khabbal Y; Elomri N; Lamsaouri J; Cherrah Y
    Therapie; 2010; 65(5):439-45. PubMed ID: 21144479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mefloquine neurotoxicity: a literature review.
    Toovey S
    Travel Med Infect Dis; 2009 Jan; 7(1):2-6. PubMed ID: 19174293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse reactions.
    Eaton L
    Nurs Times; 1996 Jun 12-8; 92(24):16-7. PubMed ID: 8716185
    [No Abstract]   [Full Text] [Related]  

  • 37. Neuropsychiatric events during prophylactic use of mefloquine before travelling.
    van Riemsdijk MM; Ditters JM; Sturkenboom MC; Tulen JH; Ligthelm RJ; Overbosch D; Stricker BH
    Eur J Clin Pharmacol; 2002 Sep; 58(6):441-5. PubMed ID: 12242605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Polymorphism at the MDR1 locus as a cause of mefloquine-induced psychosis].
    Zaigraykina N; Potasman I
    Harefuah; 2010 Sep; 149(9):583-4, 620, 619. PubMed ID: 21302473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Acute hepatitis associated with mefloquine therapy].
    Bruguera M; Herrera S
    Gastroenterol Hepatol; 2007 Feb; 30(2):102-3. PubMed ID: 17335720
    [No Abstract]   [Full Text] [Related]  

  • 40. [Adverse drug reactions (ADRs) to antimalarial drugs. Analysis of spontaneous report from the French pharmacovigilance database (1996-2000)].
    Angles A; Bagheri H; Montastruc JL; Magnaval JF;
    Presse Med; 2003 Jan; 32(3):106-13. PubMed ID: 12610379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.